36C10B22F0016↗
Technatomy Corporation received this contract from Technology Acquisition Center NJ (36C10B), Department of Veterans Affairs: $3.82M obligated so far for support- professional: other. Its period of performance ended 2024-11-09.
Key facts · data as of Oct 25, 2026
- Recipient
- Technatomy Corporation
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- Technology Acquisition Center NJ (36C10B) (36C10B)
- Obligated to date
- $3.82M
- Potential value
- $5.40M
- Ends
- 2024-11-09
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 36C10B22F0016, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_36C10B22F0016_3600_47QTCA18D00JT_4732
Technatomy Corporation: all federal awards · Department of Veterans Affairs: spending · Technology Acquisition Center NJ (36C10B): what it buys
EO14042 THE VA PHARMACY RE-ENGINEERING INBOUND EPRESCRIBING COMPONENT PROVIDES THE ABILITY TO RECEIVE INBOUND ELECTRONIC PRESCRIPTIONS FROM AN EXTERNAL PROVIDER.
What it is
- Product or service
- Support- Professional: Other (PSC R499)
- Industry
- Other Computer Related Services (NAICS 541519)
- Contracting office
- Technology Acquisition Center NJ (36C10B) (36C10B)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 47QTCA18D00JT
- Where the work is
- District of Columbia, DC · district DC-98
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
10 actions since 2022-10-26. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-05-02 | P00012 | Administrative change | -$200.9K | DE-OBLIGATE EXCESS FUNDS |
| 2024-07-29 | P00011 | Option exercised | $666.3K | EXERCISE OPTIONAL TASK |
| 2024-01-23 | P00010 | Supplemental agreement (work within scope) | $3.4K | CORRECT THE PURCHASE ORDER NUMBER (PON) FOR BILLING PURPOSES |
| 2024-01-16 | P00009 | Supplemental agreement (work within scope) | $0 | CORRECT TYPOS |
| 2024-01-11 | P00008 | Supplemental agreement (work within scope) | $0 | ADD FUNDS, SET CONTRACT CEILING AND ADDRESS TYPOS |
| 2023-11-08 | P00007 | Option exercised | $1.51M | ADD FUNDS |
| 2023-06-14 | P00006 | Funding only | $360.8K | ADD FUNDS |
| 2023-01-10 | P00005 | Funding only | -$815 | DE-OBLIGATE EXCESS FUNDS |
| 2022-11-07 | P00004 | Funding only | $6.3K | ADDITIONAL FUNDS REQUIRED TO ENSURE COMPLETION OF BASE YEAR |
| 2022-10-26 | P00003 | Option exercised | $1.47M | OPTION PERIOD 1 EXERCISED FOR PHARMACY RE-ENGINEERING INBOUND EPRESCRIBING |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗